CM: General Concepts in TB Treatment
- Strategies for TB Treatment
- Pharmacological Basis of treatment
- Treatment Phases
- Fixed Dose Combinations [FDC]s
- Advantages of FDCs
- FDCs used in NTEP
- First line anti TB drugs
- Second Line anti TB drugs
- Types of Drug Resistance Tuberculosis -DRTB
- TB Drug Regimen
- DR-TB Treatment Regimens
- TB Treatment Initiation
- Pre-treatment Evaluation of TB patients
- Follow-up of TB patient
- Follow-up sputum examination
- TB Treatment Outcome
- Long Term Post-treatment follow up of TB patients
- Active TB Drug Safety Monitoring [aDSM]
- Transfer of TB Patient Ownership
CM: DS-TB Treatment and Care
CM: Overview of DR-TB Treatment and care
- DR-TB Centres and Network
- DR-TB Treatment Regimens
- Adverse Drug Reactions(ADRs) to Second Line Treatment
- Manage TB India Application
- Pre-treatment Counselling of DR-TB Patients
- Pre treatment evaluation of a DRTB cases
- Interim Treatment Outcomes of DR-TB Cases
- Final Treatment Outcomes of DR-TB Cases
- Follow-up Monitoring of DR-TB Patients
- Follow up sputum examination for DR-TB
CM: Isoniazid [H] Mono/Poly DR-TB Regimen
- Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation
- EVIDENCE FOR ISONIAZID[H] MONO/POLY DR-TB REGIMEN
- Eligibility Criteria for H Mono/poly DR-TB Regimen
- Eligibility Criteria for H Mono/poly DR-TB Regimen
- Replacement Sequence in the H Mono/Poly DR-TB
- Follow up sputum examination for Isoniazid [H] Mono/Poly DR-TB Regimen
CM: Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE]
- Shorter oral Bedaquiline-containing MDR/RR-TB regimen: Evidence
- Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment
- Shorter oral Bedaquiline-containing MDR/RR-TB regimen
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Dosage of Drugs for Adults
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Replacement Sequence of Drugs
- Follow up sputum examination for Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- List of Drugs that can be Used Safely or Avoided along with Bedaquiline
CM: Longer Oral M/XDR-TB Regimen
- Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen
- Eligibility Criteria for Longer Oral M/XDR-TB Regimen
- Longer Oral M/XDR-TB: Regimen and Duration
- Treatment Extension in Longer Oral M/XDR-TB Regimen
- Dosages of M/XDR-TB Drugs for Adult in Longer Oral M/XDR-TB Regimen
- Details of Replacement Sequence of Drugs in Longer Oral M/XDR-TB Regimen
- Follow up sputum examination for Longer Oral M/XDR-TB DR-TB Regimen
CM: Treatment Support
CM: Adherence Management
- TB Treatment Adherence
- Importance of Treatment adherence
- Recording and Monitoring Adherence
- Digital Adherence Monitoring Technologies
- Directly Observed Treatment
- Recording Adherence in Treatment card
- Recording Adherence using TB Arogya Sathi Application
- 99 DOTS- Features and Benefits
- 99 DOTS- Envelopes
- 99 DOTS- Envelope Dispensing Process
- 99 DOTS- Initiating adherence monitoring of the patient
- 99 DOTS- Self Reporting Adherence
- Medication Event Reminder Monitor [MERM] Boxes
- MERM Patient Register
- Monitoring of Adherence by NTEP Staff
- Adherence Summary Dashboard
- Management of Patients with Treatment Interruptions
- Adherence Register
CM: ADRs to ATT
- Adverse Drug Reactions
- Types of ADR of TB Treatment
- Management of Adverse Drug Reactions(ADRs) of TB Treatment
- Active TB Drug Safety Monitoring [aDSM]
- Pharmacovigilance in NTEP
- Possible Adverse Events Due to Drugs in Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen
- Adverse Drug Events: H Mono/Poly DR-TB Regimen
- Adverse Drug Reactions(ADRs) to Second Line Treatment
- Management of ADR: Rash, Allergy and Anaphylaxis Reaction
- Management of DR-TB ADR: Gastrointestinal Symptoms [Gastritis and abdominal pain]
- Management of DR-TB ADR: Diarrhoea and/or Flatulence
- Management of DR-TB ADR: Hepatitis
- Management of DR-TB ADR: Giddiness
- Management of DR-TB ADR: QT Prolongation
- Management of DR-TB ADR: Hematological Abnormalities
- Management of DR-TB ADR: Hypothyroidism
- Management of DR-TB ADR: Arthralgia
- Management of DR-TB ADR: Peripheral Neuropathy
- Management of DR-TB ADR: Psychotic Symptoms
- Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity]
- Management of DR-TB ADR: Vestibular Toxicity
CM: Monitoring of Treatment
- Monitoring indicator for TB Treatment outcome
- Monitoring indicators related to DR-TB Treatment
- NTEP Performance Indicator - Treatment Success Rate
- NTEP Performance Indicator – Percentage Of Multidrug-resistant (MDR)/ Rifampicin-resistant (RR) Patients Initiated on Treatment Out of Totally Diagnosed
- RCA for low performance in in Percentage Treatment initiation of RR/MDR-TB Cases
- DRTB Treatment Register
- Follow-Up Register
- DRTB Follow Up Register
Cover
TB Treatment